Health Trials

About this trial

The SAHARA trial assesses wether combining ultrahypofractionated accelerated radiotherapy (RT) with hyperthermia is as effective as standard hypofractionated high-dose radiation in treating non-melanoma skin cancer (NMSC).

Eligibility criteria

Qualifiers

Personally signed and dated written informed consent

Histologically confirmed invasive non-melanoma skin cancer (NMSC), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of any differentiation

≥ T2 (TNM Classification 8th Edition)

Tumor thickness up to 2cm (Maximum Depth invasion and/or exophytic growth, measured on pathology report or imaging)

Disqualifiers

Other histology than BCC or SCC

T1 tumor and/or N+ (according to TNM classification 8th edition)

Tumors after resection (R1 or R2 as well as adjuvant indication)

Tumor invasion into critical areas

Trial design

Treatments tested in this trial

  • Water-filtered infrared-A-hyperthermia (wIRA) hyperthermia combined
  • Radiotherapy (RT)

Treatment groups

100 Participants
are divided into 2 treatment groups

Locations

4
Kantonsspital Aarau5001, AarauCanton of Aargau, Switzerland
Kantonsspital Winterthur8401, WinterthurCanton of Zurich, Switzerland
Lindenhofgruppe3001, Bern Switzerland
Luzerner Kantonsspital6000, Lucerne Switzerland

Sponsors and collaborators

Kantonsspital Winterthur KSW

Lead sponsor

Luzerner Kantonsspital

Collaborator

Lindenhofgruppe AG

Collaborator

Kantonsspital Aarau

Collaborator

Source ClinicalTrials.gov